Year-end Sale % OFF 
Abstract
Clindamycin phosphate, a new parenteral ester of clindamycin, was given to 219 patients, 202 with established infections and 17 as prophylactic antibiotic therapy. One hundred and two of the infections were considered to be severe and 92 moderately severe. One hundred and seventy-four of the infections were related to the gastrointestinal tract, and 22 to the genital tract. Recognized bacterial pathogens were isolated from 72% of specimens examined in 149 patients and E. coli, Bacteroides fragilis and various species of streptococci were the commonest organisms found. Clindamycin treatment was started in the immediate post-operative period in 175 patients and for complications in 44 patients. Eighty per cent of patients showed an excellent clinical and bacteriological response to treatment and there was no difference in the cure rates obtained using clindamycin alone or in combination with other antibiotics. Significant gastrointestinal side effects were seen in 13% of patients and these were related to the sex and age of the patient but not to changes in the faecal flora or the primary clinical condition. Pseudomembranous colitis was not seen.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
